# US 2015/0284814 A1 · Viruses associated with immunodeficiency and enteropathy and methods using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0284814 A1
- Document ID: US20150284814A1
- Status: Published application
- Kind: A1
- Application number: 14/429,559
- Filed: 2013-09-19
- Published: 2015-10-08
- Earliest claimed: 2012-09-19
- Assignees: Beth Israel Deaconess
- Applicants: Beth Israel Deaconess Medical Center, Inc.; Washington University
- Inventors: Dan Barouch; Herbert W. Virgin; David Wang; Guoyan Zhao; Larissa Thackray; Scott Handley; Rachel Presti
- Web page: https://patentgrep.com/patent/US20150284814A1

## CPC

- C12Q 1/703: {Viruses associated with AIDS}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C12N 2710/10321: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/20021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/22021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2720/00021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2750/14021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2750/14121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2770/16021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2770/32021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2770/32321: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to previously undescribed viruses that are associated with significant expansion of the virome, immunodeficiency, and enteropathy during lentiviral infection. The invention also provides methods to detect acquired immune deficiency syndrome (AIDS) or AIDS progression in a subject, methods to diagnose immunodeficiency or enteropathy in a subject, and methods to identify a therapeutic agent to treat the same.

## Claims

### Claim at position 1

1-32. (canceled)

### Claim 33

A method of detecting acquired immune deficiency syndrome (AIDS) and/or AIDS progression in a subject, said method comprising:
a) synthesizing cDNA from RNA by a biological sample obtained from as subject; and
b) detecting if present in the sample one or more target nucleotide sequences that specifically hybridize wider stringent conditions to one or more polynucleotides having at least 70% sequence identity with any one of SEQ ID NO:1-107 by a PCR assay selected from the group consisting of a real time PCR assay and a nested PCR assay; and
determining the magnitude of difference between the level of said one or more target nucleotide sequences in said subject relative to the level of said one or more target nucleotide sequences from a control subject whereby an increase in the level of said one or more target nucleotide sequences in said subject, relative to the level of the one or more target nucleotide sequences from a control subject, indicates AIDS and/or AIDS progression in said subject.

### Claim 34

A method of diagnosing, or providing a prognostic indicator of, immunodeficiency and/or enteropathy in a subject, said method comprising:
providing at least one biological sample from the subject;
subjecting RNA if present from the at least one biological sample to synthesis of cDNA comprising one or more target nucleotide sequences that specifically hybridize under stringent conditions to one or more of polynucleotides having a sequence that is at least 70% identical to the sequence of a polynucleotide selected from the group consisting of SEQ ID NO:1-107;
detecting said one or more target nucleotide sequences by a PCR assay selected from the group consisting of a real time PCR assay and a nested PCR assay; and
determining the magnitude of difference between the level of said one or more target nucleotide sequences in said subject relative to the level of one more target nucleotide sequences from a control subject wherein the detection of an increase in the level of said one or more target nucleotide sequences in said subject, relative to the level of one or more target nucleotide sequences from a control subject, indicates the presence of, or the propensity to develop, immunodeficiency and/or enteropathy in said subject.

### Claim 35

A method of identifying a therapeutic agent for treating immunodeficiency and/or enteropathy in a subject, said method comprising:
providing a first sample from the subject prior to administration of a candidate therapeutic agent;
administering a therapeutically effective amount of the candidate therapeutic agent to the subject;
providing a second sample from the subject after the administering the candidate therapeutic agent;
detecting in the first sample by a first PCR assay one or more target polynucleotides that specifically hybridize under stringent conditions to one or more polynucleotides having a sequence that is at least 70% identical to the sequence of a polynucleotide selected from the group consisting of SEQ ID NO: 1-107;
detecting in the second sample by a second PCR assay the one or more target polynucleotides, wherein the detection of a decrease in the level of said one or more target nucleotide sequences in said second sample, relative to the level of the one or more target nucleotide sequences from said first sample, identifies said candidate agent as said therapeutic agent.

### Claim 36

(canceled)

### Claim 37 (depends on 35)

The method of claim 35, wherein said immunodeficiency or enteropathy is associated with a lentivirus.

### Claim 38 (depends on 37)

The method of claim 37, wherein said immunodeficiency and enteropathy are associated with a lentivirus.

### Claim 39 (depends on 37)

The method of claim 37, wherein said lentivirus is human immunodeficiency virus (HIV) or simian immunodeficiency virus (SIV).

### Claim 40 (depends on 35)

The method of claim 35, wherein the detecting in the first sample one or more target nucleotide sequences comprises synthesizing cDNA from RNA comprised by said sample.

### Claim 41

(canceled)

### Claim 42 (depends on 40)

The method of claim 40, wherein said first PCR assay is selected from the group consisting of a real time PCR (RT-PCR) assay and a nested PCR assay.

### Claim 43 (depends on 33)

The method of claim 33, wherein said sample is a tissue, organ, liquid, or feces sample.

### Claim 44 (depends on 43)

The method of claim 43, wherein said subject is a mammal.

### Claim 45 (depends on 44)

The method of claim 44, wherein said mammal is a primate.

### Claim 46 (depends on 45)

The method of claim 45, wherein said primate is a human.

### Claim 47 (depends on 38)

The method of claim 38, wherein said lentivirus is human immunodeficiency virus (HIV).

### Claim 48 (depends on 38)

The method of claim 38, wherein raid lentivirus is simian immunodeficiency virus (SIV).

### Claim 49 (depends on 34)

The method of claim 34, wherein said immunodeficiency or enteropathy is associated with a lentivirus.

### Claim 50 (depends on 49)

The method of claim 49, wherein said lentivirus is human immunodeficiency virus (HIV).

### Claim 51 (depends on 49)

The method of claim 49, wherein said lentivirus is simian immunodeficiency virus (SIV).

### Claim 52 (depends on 33)

The method of claim 33, wherein said sample is a feces sample.

### Claim 53 (depends on 34)

The method of claim 34, wherein said sample is a feces sample.

### Claim 54 (depends on 35)

The method of claim 35, wherein said first sample is a first feces sample an said second sample is a second feces sample.
